Company intelligence / Profile preview
LyncBio Therapeutics
Taipei, Taiwan
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
LyncBio Therapeutics is a biotechnology company dedicated to the discovery and development of innovative therapies for cancer, with a primary focus on next-generation antibody-drug conjugates (ADCs) and small molecule inhibitors. Utilizing its proprietary Lync-ADC platform, the company designs therapies with improved stability and widened therapeutic windows to treat various solid tumors. Their lead programs include LB-101, a TROP2-directed ADC, and LB-201, a small molecule targeting KRAS mutations. LyncBio operates with a global footprint, maintaining research and development facilities in both Taiwan and the United States. The company is positioned to advance its pipeline into clinical trials to address significant unmet needs in oncology.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateSmall molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on LyncBio Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LyncBio Therapeutics.